FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Azurity Selling Unapproved Drugs: FDA

[ Price : $8.95]

FDA warns Wilmington, MA-based Azurity Pharmaceuticals it is manufacturing and marketing unapproved new drugs with CGMP violations...

Regulatory Review Period for Quviviq

[ Price : $8.95]

Federal Register notice: FDA determines for patent extension purposes the regulatory review period for Idorsia Pharmaceuticals Quv...

ODAC Discussing Immune Checkpoint Inhibitors

[ Price : $8.95]

FDA issues two briefing documents to facilitate discussion by the Oncology Drugs Advisory Committee of the risk/benefit assessment...

4 NDAs Withdrawn Over Annual Reports

[ Price : $8.95]

Federal Register notice: FDA withdraws approval of four NDAs from multiple sponsors because they repeatedly failed to file require...

Topside Change at CDRH Continues its Corruption

[ Price : $8.95]

FDA Webview editor Jim Dickinson analyzes the evolving legacy of departing CDRH director Jeff Shuren and his hand-picked interim s...

Koreas C&T Dream Co. Gets Form-483

[ Price : $8.95]

A 2023 inspection at South Koreas C&T Dream Co. leads to a nine-observation FDA Form-483 that cites significant GMP deviations.

Gilead Recalls Veklury Over Glass Particle

[ Price : $8.95]

Gilead Sciences recalls one lot of Veklury (remdesivir) for injection 100 mg/vial, after it received a customer complaint about th...

FDA Taps Industry Vet as Device Evaluation Chief

[ Price : $8.95]

FDA has appointed industry veteran and consultant Ross Segan as CDRH Office of Product Evaluation and Quality director, replacing ...

Ideaya Bio Plans Phase 3 for Darovasertib

[ Price : $8.95]

Ideaya Biosciences says it is advancing darovasertib into a Phase 3 trial following positive interim Phase 2 clinical trial data o...

3 Guides on Device Conformity Assessment Program

[ Price : $8.95]

Federal Register notice: FDA makes available three draft guidances for its Accreditation Scheme for Conformity Assessment Program.